These compounds with IC50 for CK1δ in nanomolar scale were predicted to cross BBB and showed protective effect on in vivo hTDP-43 neurotoxicity Drosophila model, which makes them potential pharmacological treatment of human TDP-43 proteinopathies such as ALS as well as other neurodegenerative disorders connected with abnormal CK1 activity.6 Here, CSNK1A1 is linked to amyotrophic lateral sclerosis.